Alnylam Pharmaceuticals (ALNY) Shareholder 683 Capital Management Cut Its Holding as Share Price Rose; Prospect Capital (PSEC) Shareholder Shufro Rose & Co Cut Stake by $958,188

May 23, 2018 - By Clifton Ray

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Shufro Rose & Co Llc decreased its stake in Prospect Capital Corporation (PSEC) by 92.15% based on its latest 2017Q4 regulatory filing with the SEC. Shufro Rose & Co Llc sold 159,698 shares as the company’s stock declined 9.64% with the market. The institutional investor held 13,602 shares of the company at the end of 2017Q4, valued at $92,000, down from 173,300 at the end of the previous reported quarter. Shufro Rose & Co Llc who had been investing in Prospect Capital Corporation for a number of months, seems to be less bullish one the $2.49 billion market cap company. The stock increased 0.81% or $0.055 during the last trading session, reaching $6.855. About 964,424 shares traded. Prospect Capital Corporation (NASDAQ:PSEC) has declined 27.59% since May 23, 2017 and is downtrending. It has underperformed by 39.14% the S&P500.

683 Capital Management Llc decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 16.49% based on its latest 2017Q4 regulatory filing with the SEC. 683 Capital Management Llc sold 39,500 shares as the company’s stock rose 5.82% while stock markets declined. The hedge fund held 200,000 shares of the health care company at the end of 2017Q4, valued at $25.41M, down from 239,500 at the end of the previous reported quarter. 683 Capital Management Llc who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $9.85B market cap company. The stock decreased 1.01% or $1 during the last trading session, reaching $97.96. About 450,541 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 23, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Since December 8, 2017, it had 25 buys, and 0 selling transactions for $21.04 million activity. $67,500 worth of stock was bought by Eliasek M Grier on Monday, December 11. The insider Stark Eugene S bought $6,500. $24,293 worth of Prospect Capital Corporation (NASDAQ:PSEC) was bought by Van Dask Kristin Lea on Friday, May 18.

Analysts await Prospect Capital Corporation (NASDAQ:PSEC) to report earnings on August, 27. They expect $0.19 EPS, 0.00% or $0.00 from last year’s $0.19 per share. PSEC’s profit will be $69.02 million for 9.02 P/E if the $0.19 EPS becomes a reality. After $0.19 actual EPS reported by Prospect Capital Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Shufro Rose & Co Llc, which manages about $1.64B and $1.02B US Long portfolio, upped its stake in J & J Snack Foods Corp (NASDAQ:JJSF) by 3,000 shares to 23,277 shares, valued at $3.53 million in 2017Q4, according to the filing. It also increased its holding in Arconic Inc by 19,887 shares in the quarter, for a total of 383,119 shares, and has risen its stake in Welltower Inc.

Investors sentiment decreased to 0.7 in Q4 2017. Its down 0.29, from 0.99 in 2017Q3. It turned negative, as 31 investors sold PSEC shares while 68 reduced holdings. 33 funds opened positions while 36 raised stakes. 46.56 million shares or 10.71% less from 52.14 million shares in 2017Q3 were reported. Eagle Limited Liability Com reported 0.02% in Prospect Capital Corporation (NASDAQ:PSEC). Live Your Vision Ltd Liability reported 0% of its portfolio in Prospect Capital Corporation (NASDAQ:PSEC). Vantage Invest Llc holds 0% or 1,062 shares. Fincl Architects Incorporated invested 0.01% of its portfolio in Prospect Capital Corporation (NASDAQ:PSEC). Bankshares Of Montreal Can has invested 0.01% in Prospect Capital Corporation (NASDAQ:PSEC). Quinn Opportunity Ptnrs Ltd Liability Com owns 668,900 shares. Mckinley Mngmt Ltd Llc Delaware reported 765,052 shares stake. Raymond James Fincl Ser Advsr Incorporated holds 0.01% or 185,799 shares. Taylor Frigon Cap Limited Liability has 129,905 shares. 79,331 were reported by Hightower Advisors Ltd Llc. 400 are owned by Markston Ltd Liability Corp. Envestnet Asset has 0% invested in Prospect Capital Corporation (NASDAQ:PSEC) for 12,152 shares. Advisory has 397,659 shares. Goldman Sachs Grp has 92,399 shares. Quantbot Tech Limited Partnership has 0.02% invested in Prospect Capital Corporation (NASDAQ:PSEC).

More notable recent Prospect Capital Corporation (NASDAQ:PSEC) news were published by: Seekingalpha.com which released: “Prospect Capital’s (PSEC) CEO John Francis Barry on Q3 2018 Results – Earnings Call Transcript” on May 11, 2018, also Nasdaq.com with their article: “Prospect Capital Announces Issuance of $103.5 Million of 4.95% Convertible Notes due 2022” published on May 18, 2018, Seekingalpha.com published: “Prospect Capital announces add-on notes offering” on May 15, 2018. More interesting news about Prospect Capital Corporation (NASDAQ:PSEC) were released by: Seekingalpha.com and their article: “Cautious Prospect Capital up 1.25% after FQ3 beat” published on May 09, 2018 as well as Streetinsider.com‘s news article titled: “Prospect Capital (PSEC) Reports Issuance of $103.5 Million of 4.95% Convertible Notes due 2022” with publication date: May 18, 2018.

Among 9 analysts covering Prospect Capital Corporation (NASDAQ:PSEC), 1 have Buy rating, 2 Sell and 6 Hold. Therefore 11% are positive. Prospect Capital Corporation had 16 analyst reports since August 27, 2015 according to SRatingsIntel. Wells Fargo downgraded the shares of PSEC in report on Monday, January 11 to “Underperform” rating. The rating was maintained by BMO Capital Markets on Friday, October 6 with “Hold”. The stock has “Neutral” rating by National Securities on Friday, January 29. The rating was maintained by BMO Capital Markets on Wednesday, May 31 with “Hold”. FBR Capital maintained Prospect Capital Corporation (NASDAQ:PSEC) rating on Wednesday, August 31. FBR Capital has “Outperform” rating and $10 target. The firm has “Market Perform” rating by BMO Capital Markets given on Friday, November 10. The firm earned “Market Perform” rating on Wednesday, August 30 by Raymond James. The firm has “Underperform” rating by Raymond James given on Thursday, February 11. The rating was downgraded by FBR Capital to “Market Perform” on Thursday, May 11. As per Thursday, February 11, the company rating was maintained by RBC Capital Markets.

Since January 4, 2018, it had 0 buys, and 10 insider sales for $38.04 million activity. The insider Ausiello Dennis A sold 17,117 shares worth $2.57 million. $234,033 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by KEATING LAURIE. Greene Barry E had sold 38,460 shares worth $5.50 million. The insider Vaishnaw Akshay sold $12.67M. 15,000 shares valued at $2.24M were sold by SHARP PHILIP A on Tuesday, March 13. Another trade for 36,745 shares valued at $4.84M was made by Mason Michael on Thursday, January 4.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. Credit Suisse maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, September 21. Credit Suisse has “Outperform” rating and $123 target. The firm has “Outperform” rating by Credit Suisse given on Thursday, October 6. The firm earned “Sell” rating on Friday, September 15 by Nomura. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Jefferies on Thursday, October 6. TheStreet downgraded the shares of ALNY in report on Saturday, August 22 to “Hold” rating. On Friday, November 17 the stock rating was maintained by Piper Jaffray with “Buy”. On Sunday, January 7 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Tuesday, February 16 by Leerink Swann. The company was maintained on Wednesday, November 16 by Needham. As per Tuesday, August 2, the company rating was initiated by Morgan Stanley.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 EPS, down 27.61% or $0.37 from last year’s $-1.34 per share. After $-1.41 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28% negative EPS growth.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” on April 25, 2018, also Seekingalpha.com with their article: “Alnylam on go with late-stage study of lumasiran in PH1” published on May 03, 2018, Seekingalpha.com published: “Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation” on April 30, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Fool.com and their article: “Alnylam Looks Forward” published on May 08, 2018 as well as Nasdaq.com‘s news article titled: “Ionis Pharmaceuticals Prepares for Launch” with publication date: May 09, 2018.

Prospect Capital Corporation (NASDAQ:PSEC) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>